Liting  Wang

Hainan Institute of Biotechnology, Haikou, 570206, Hainan, China
Author    Correspondence author
Cancer Genetics and Epigenetics, 2024, Vol. 12, No. 2   
Received: 28 Feb., 2024    Accepted: 05 Apr., 2024    Published: 18 Apr., 2024

This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Prostate cancer is one of the most common cancers among men worldwide, and early screening and diagnosis are essential for improving treatment outcomes. This study emphasizes genetic susceptibility and key genetic markers such as BRCA1, BRCA2, and HOXB13, analyzing their variability across different ethnic groups and exploring advanced genetic screening technologies such as Next-Generation Sequencing (NGS), Genome-Wide Association Studies (GWAS), and liquid biopsies. These technologies have improved the precision of screening and helped reduce overdiagnosis and overtreatment. However, the application of these technologies also faces challenges such as genetic heterogeneity, ethical issues, and the accessibility and cost-effectiveness of screening. This research deeply investigates the critical role of genetic markers in the early screening of prostate cancer, particularly in predicting the disease's genetic susceptibility, with the goal of further optimizing early screening and management strategies for prostate cancer through genetics.

Prostate cancer; Genetic susceptibility; Genetic markers; Next-generation sequencing (NGS); Genome-wide association studies (GWAS)